Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and   Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. , June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based

Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J. , June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy

25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez , MD LAWRENCEVILLE, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines,

49% of S hares V oted, Q uorum N ot E stablished   To Hold Annual Meeting Polls Remain Open Stockholders H olding U nvoted Proxies A re S trongly E ncouraged to V ote T heir S hares LAWRENCEVILLE, N.J. , June 04, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage

Calls for All Shareholders to Vote so Quorum Requirement t o Hold The Meeting is Met LAWRENCEVILLE, N.J. , May 27, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today reminded

Focus on Immuno-Oncology and  Next-Generation Vaccines is Suppor ted with a Strong Balance Sheet Conference Call Begins at 10:00 a.m. Eastern Time Today LAWRENCEVILLE, N.J. , May 14, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company focused on

Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J. , May 11, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based

LAWRENCEVILLE, N.J. , May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 10:00 a.m.

LAWRENCEVILLE, N.J. , April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management participated in Alliance Global Partners’ (AGP) Virtual Series on April 21, 2021 .

Lawrenceville, NJ , April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net